Skip to content
DataLookout
Menu

NCT04541082

Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 8 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 15 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Final enrollment: 35 participants (planned 102)
    • Site details revised
  2. Notable Primary completion pushed from Jul 2026 to Mar 31, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 61 words
    • Study completion pushed from Dec 2026 to Sep 30, 2027
    • Study description shortened, about 19 words
    • Publications: details revised at 1 of 1 entry
  3. Notable Primary completion date: Dec 2025 to Jul 2026v15
  4. Minor Site contact updatedv14
  5. Notable Primary completion date: Sep 2024 to Dec 2025
    • Study completion date: Feb 2025 to Dec 2026
    • Site contact updated
    v12
Show 9 earlier versionsHide 9 earlier versions
  1. Notable Eligibility criteria expanded, about 3 wordsv11
  2. Notable Eligibility criteria expanded, about 1,109 words
    • Primary endpoints: 1 to 2
    • Study description expanded, about 813 words
    v10
  3. Notable Eligibility criteria expanded, about 165 words
    • Site contact updated
    v8
  4. Notable Lead sponsor: Oncoceutics, Inc. to Jazz Pharmaceuticalsv7
  5. Minor Start date changed from estimate of Oct 2020 to Oct 26, 2020v6
  6. Notable Eligibility criteria expanded, about 323 wordsv5
  7. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 2020 to Oct 2020
    • Site details revised
    v4
  8. Minor Trial status: Recruiting to Not Yet Recruiting
    • Site details revised
    v3
  9. Minor Study title shortened, about 9 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Maximum Tolerated Dose (MTD) of single-agent, oral ONC206
Timeframe: 28 Days
Number of Participants who Experienced Dose-Limiting Toxicities (DLTs)
Timeframe: 28 Days

Arms and interventions

ONC206Experimental

Drugs: ONC206

Sites

1 site in 1 country

  • National Institutes of HealthBethesda, Maryland, United States